Eli Lilly's selective amylin receptor agonist Eloralintide has produced 48-week Phase 2 data positioning it as a next-generation obesity candidate, with and without Tirzepatide co-administration.
View the full PeptX research peptide catalogue, or browse Retatrutide, Tirzepatide, Semaglutide, BPC-157, TB-500 and GHK-Cu.